KLKonstantinos Louis

Konstantinos Louis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Konstantinos Louis has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Endocrine and Molecular Mechanisms of Oocyte Aging: From Gonadotropin Signaling to Metabolic and Microenvironmental Dysfunction

    by Maria Fotara, Efthalia Moustakli, Maria Anastasia Daskalaki, Despoina Mavrogianni, Ioannis Arkoulis, Spyridon Topis, Anastasios Potiris, Konstantinos Louis, Nikolaos Kathopoulis, Ekaterini Domali, et al.

    Ovarian aging and oocyte aging are closely interconnected but distinct components of reproductive aging. Whereas ovarian aging encompasses progressive follicular depletion and changes in ovarian endocrine and somatic-cell function, oocyte aging refers more specifically to the age-associated deterioration in the molecular, cellular, and developmental competence of the oocyte. This deterioration contributes to increased aneuploidy, impaired embryonic development, implantation failure, and early pregnancy loss. This narrative review synthesizes current evidence on the endocrine, cellular, and molecular mechanisms underlying oocyte aging and their potential interactions, and examines emerging strategies for preserving oocyte competence. Age-related dysregulation of the hypothalamic–pituitary–ovarian axis, altered gonadotropin signaling, and changes in intraovarian endocrine and paracrine communication may disrupt follicular development and the follicular microenvironment. These changes may compromise functional interactions between the oocyte and surrounding somatic cells. These alterations may converge with mitochondrial dysfunction, oxidative stress, mtDNA abnormalities, impaired energy metabolism, alterations in telomere biology, and epigenetic dysregulation, ultimately compromising oocyte meiotic competence and developmental potential. Experimental strategies, including antioxidant supplementation, restoration of NAD+ metabolism, mitochondrial transfer, and exosome-based interventions, have shown potential to ameliorate features of oocyte aging, primarily in animal and preclinical models. However, none of these interventions has been shown to delay physiological oocyte aging in women, and evidence supporting their clinical effectiveness and long-term safety remains insufficient. Understanding how endocrine dysregulation interacts with metabolic, genomic, and epigenetic alterations and changes in the follicular microenvironment may facilitate the identification of biomarkers and the development of targeted approaches to preserve oocyte quality during reproductive aging.


  • Open Access

    Tumor Mutational Landscape and Its Correlation with Histopathological Characteristics in Breast Cancer

    by Eirini Papadopoulou, Maroulio Stathoulopoulou, Maria Matiatou, Panagiotis Karathanasis, Xenofon Xenakis, Grigorios Pesmatzoglou, Ioannis Fyssas, Konstantinos Louis, Dimitrios Maniatis, Anastasia Ekmektzoglou, et al.

    In breast cancer, current knowledge of the associations between clinicopathologic characteristics, genetic changes, and subtype-specific patterns remain unclear. This research investigated how pathological and clinical variables affect the actionability of NGS-based tumor molecular data. Materials and methods: 227 breast cancer patients referred to Genekor’s laboratory for tumor molecular profile analysis were included in the study. Pathology records, available in all cases, were used to assess critical clinicopathological features including HER2, ER, PR, Ki67, grade, metastatic site, and age. A 1021 gene NGS-based multigene panel was utilized to assess tumors’ biology alongside tumor mutational burden (TMB) and microsatellite instability (MSI) Results: Comprehensive genomic profiling revealed that 95.6% of the patients harbored at least one oncogenic or likely oncogenic alteration, highlighting the high diagnostic yield of NGS-based testing. Distinct subtype-specific patterns were observed: HR+/HER2-tumors were enriched for PIK3CA and ESR1 gene alterations, while Triple Negative Breast Cancer (TNBC) was dominated by TP53 alterations. Clinically actionable alterations were most common in HR+/HER2-tumors (~60% on-label), whereas TNBC more often harbored off-label or trial-associated targets. The inclusion of tumor-agnostic biomarkers (TMB/MSI) increased on-label actionability up to 64.5% in ER−/PR+ tumors. primarily driven by TMB-high cases. Median TMB values were low, and age was the only independent predictor. Furthermore, the presence of actionable alterations was significantly higher in metastatic tumors, and TP53 alterations were associated with aggressive tumor characteristics.Conclusions: Comprehensive NGS-based genomic profiling identifies clinically actionable alterations in over half of breast cancer patients, with substantial variability across molecular subtypes. The HR+/HER2-subtype demonstrates the highest prevalence of on-label actionable biomarkers. These findings support the routine implementation of comprehensive genomic profiling, especially in metastatic HER2-negative breast cancer, to guide precision oncology strategies and enable enrollment in biomarker-driven clinical trials.

  • Open Access

    Evaluating the Association of Ki-67 with Oncotype DX Recurrence Score in Early-Stage ER-Positive/HER2-Negative Breast Cancer

    by Dimitrios Dragoumis, George Kapetsis, Konstantinos Louis, Dimitrios Maniatis, Eleni Mpalampou, Konstantinos Bouloukos, Xenophon Xenakis, Nikolaos Papaioannou, Styliani Parpoudi, Grigorios Pesmatzoglou, et al.

    Background/Objectives: Ki-67 is widely used as an immunohistochemical marker of tumor proliferation in hormone receptor-positive (HR-positive), HER2-negative breast cancer, but its interpretation is limited by variability and uncertain concordance with genomic assays. The Oncotype DX® Recurrence Score (RS) is a validated multigene assay with established prognostic and predictive utility. This study evaluated the relationship between Ki-67 and RS in clinical practice. Methods: We retrospectively analyzed women in Greece with early-stage estrogen receptor-positive, HER2-negative breast cancer without distant metastasis (pM0) who underwent Oncotype DX testing between 2020 and 2023. Eligible patients were node-negative or postmenopausal with node-positive disease. RS was categorized as low (0–25) or high (>25). Ki-67 was assessed using binary (5–p < 0.001). After stratification, associations with RS were observed only in tumors with high Ki-67 expression, whereas no correlation was detected in low or intermediate groups. RS distributions differed significantly across Ki-67 strata. Overall concordance between Ki-67-based proliferation categories and RS-based genomic risk was 56.2%, with discordant cases in both directions. Conclusions: Ki-67 shows a modest association with Oncotype DX RS, but substantial discordance indicates Ki-67 should not substitute genomic testing in HR-positive/HER2-negative early breast cancer.

  • Open Access

    Evaluating the Association of Ki 67 with Oncotype DX Recurrence Score in Early-Stage ER Positive/HER2 Negative Breast Cancer

    by Dimitrios Dragoumis, George Kapetsis, Konstantinos Louis, Dimitrios Maniatis, Eleni Mpalampou, Konstantinos Bouloukos, Xenophon Xenakis, Nikolaos Papaioannou, Styliani Parpoudi, Grigorios Pesmatzoglou, et al.

    Background/Objectives Ki‑67 is widely used as an immunohistochemical marker of tumor proliferation in hormone receptor–positive (HR‑positive), HER2‑negative breast cancer, but its inter-pretation is limited by variability and uncertain concordance with genomic assays. The Oncotype DX® Recurrence Score (RS) is a validated multigene assay with established prognostic and predictive utility. This study evaluated the relationship between Ki‑67 and RS in clinical practice. Methods We retrospectively analyzed women in Greece with early‑stage estrogen receptor–positive, HER2‑negative breast cancer without distant metastasis (pM0) who under-went Oncotype DX testing between 2020 and 2023. Eligible patients were node nega-tive or postmenopausal with node positive disease. RS was categorized as low (0–25) or high (>25). Ki‑67 was assessed using binary (< 20% vs ≥20%) and three‑tier (≤5%, >5%–< 30%, ≥30%) classifications. Associations were analyzed using correlation, con-cordance, and nonparametric methods. Results Among 2,967 patients, the median RS was 16, with similar distributions across nodal subgroups. Ki‑67 and RS demonstrated a moderate positive correlation as continuous variables (r = 0.42, p < 0.001). After stratification, associations with RS were observed only in tumors with high Ki‑67 expression, whereas no correlation was detected in low or intermediate groups. RS distributions differed significantly across Ki‑67 strata. Overall concordance between Ki‑67‑based proliferation categories and RS‑based ge-nomic risk was 56.2%, with discordant cases in both directions. Conclusions Ki‑67 shows a moderate association with Oncotype DX RS, but substantial discordance indicates it should not substitute genomic testing in HR‑positive/HER2‑negative early breast cancer.

  • Open Access

    Thrombocytopenia in Pregnancy: Clinical Challenges, Maternal–Fetal Risks, and Management Strategies

    by Sofoklis Stavros, Nikolaos Kathopoulis, Angeliki Gerede, Themos Grigoriadis, Efthalia Moustakli, Athanasios Zikopoulos, Nefeli Arkouli, Pavlos Machairoudias, Maria Tzeli, Ismini Anagnostaki, et al.

    Thrombocytopenia affects up to 10% of pregnant women and represents the second most common blood disorder during pregnancy. Its causes include immune-mediated thrombocytopenia, hemolysis, elevated liver enzymes and low platelet count (HELLP) syndrome, preeclampsia (PE), and benign pregnant thrombocytopenia. Diagnosis is crucial because the cause dictates the effect on maternal health, pregnancy management, and neonatal outcomes. This narrative review examines the range of thrombocytopenia during pregnancy, primarily focusing on diagnostic evaluation, underlying pathophysiological causes, and differential diagnosis. In addition, it organizes maternal and fetal complications that might be caused by the condition, such as bleeding, preterm birth, and neonatal thrombocytopenia. Moreover, current patient management based on available evidence and clinical practice is discussed, including immunomodulatory therapies, platelet transfusions, clinical monitoring, and supportive care. A thorough and clinically guided approach to thrombocytopenia in pregnancy is indispensable for maximizing maternal and fetal outcomes and facilitating the personalization of perinatal care.

  • Top Cited Papers
    Open Access

    Linking Oxidative Stress to Placental Dysfunction: The Key Role of Mitochondria in Trophoblast Function

    by Ioanna Vasilaki, Anastasios Potiris, Efthalia Moustakli, Despoina Mavrogianni, Nikoletta Daponte, Theodoros Karampitsakos, Alexios Kozonis, Konstantinos Louis, Christina Messini, Themos Grigoriadis, et al.

    Oxidative stress (OS) is a critical regulator of placental development; however, its specific effects on trophoblast biology remain incompletely elucidated. This narrative review synthesizes evidence derived from studies using human placental tissues and trophoblast cell models to delineate how excessive reactive oxygen species (ROS) disrupt molecular and cellular pathways essential for normal placentation. The literature search was restricted to human-based and in vitro investigations. Across these studies, OS was consistently shown to impair mitochondrial function in trophoblasts, resulting in increased mitochondrial ROS generation, loss of mitochondrial membrane potential, and activation of apoptotic signaling cascades. These mitochondrial disturbances were associated with reduced trophoblast proliferation, migration, and invasion, as well as dysregulation of angiogenic balance. Furthermore, several studies reported alterations in mitophagy, involvement of redox-sensitive pathways such as CYP1A1 and KLF9, and the extracellular release of mitochondrial DNA, which was linked to reduced cell viability and increased necrotic cell death. Collectively, the available evidence indicates that OS interferes with key trophoblast-dependent developmental processes, providing mechanistic insight into the pathogenesis of placental dysfunction observed in pregnancy complications such as preeclampsia (PE) and intrauterine growth restriction (IUGR). Elucidation of these pathways may inform the development of targeted therapeutic strategies aimed at preserving placental function and improving adverse pregnancy outcomes.


  • Top Cited Papers
    Open Access

    Artificial Intelligence in Recurrent Pregnancy Loss: Current Evidence, Limitations, and Future Directions

    by Athanasios Zikopoulos, Efthalia Moustakli, Anastasios Potiris, Konstantinos Louis, Ioannis Arkoulis, Aikaterini Lydia Vogiatzoglou, Maria Tzeli, Nikolaos Kathopoulis, Panagiotis Christopoulos, Nikolaos Thomakos, et al.

    Background: Despite significant advances in genetics, immunology, and endometrial research, the underlying cause of nearly half of recurrent pregnancy loss (RPL) cases remains unknown. This highlights the limitations of conventional diagnostic approaches and underscores the need for methods that can detect complex, subtle biological patterns. Objectives: To summarize and critically assess how artificial intelligence (AI) is changing our knowledge of, ability to predict, and future therapeutic management of RPL, with a focus on machine learning (ML) approaches that identify latent biological pathways and multifactorial contributors to pregnancy loss. Methods: This narrative review summarizes contemporary research on AI applications in reproductive medicine. Research using imaging, proteomic, genomic, clinical, and multi-omics information to create predictive or mechanistic models associated with RPL provided evidence. Results: AI-based approaches are increasingly demonstrating the ability to detect complex interactions among environmental, immunological, biochemical, and genetic factors associated with RPL. ML and deep learning (DL) models enhance prognostic accuracy, identify novel candidate biomarkers, and provide insights into the systemic and molecular mechanisms underlying pregnancy loss. Integrating heterogeneous data through AI supports the development of personalized reproductive profiles and can improve prediction and counseling. Conclusions: AI has the potential to improve both personalized prediction and mechanistic understanding of RPL. However, clinical translation is currently hampered by a number of important issues, including small and diverse datasets, conflicting diagnostic definitions, limited external validation, and a lack of prospective clinical trials. To responsibly integrate AI tools into reproductive care, these limitations must be addressed.


  • Open Access

    Endocrine-Disrupting Chemicals and Male Infertility: Mechanisms, Risks, and Regulatory Challenges

    by Sofoklis Stavros, Nikolaos Kathopoulis, Efthalia Moustakli, Anastasios Potiris, Ismini Anagnostaki, Spyridon Topis, Nefeli Arkouli, Konstantinos Louis, Charalampos Theofanakis, Themos Grigoriadis, et al.

    Male reproductive health is increasingly threatened by endocrine-disrupting chemicals (EDCs), which interfere with hormonal homeostasis and reproductive physiology. Rising rates of male infertility have been linked to greater exposure to pollutants such as heavy metals, phthalates, pesticides, and bisphenol A. These compounds act through multiple mechanisms, including oxidative stress, apoptosis, receptor-mediated disruption of estrogenic and androgenic signaling, alterations in the hypothalamic–pituitary–gonadal (HPG) axis, and heritable epigenetic changes. Such disruptions impair key outcomes like sperm concentration, motility, morphology, DNA integrity, and steroidogenesis. Evidence from animal studies and human epidemiology consistently demonstrates these harmful effects, with biomarkers of EDC exposure correlating with reduced semen quality, hormonal imbalances, and infertility. Beyond individual health, infertility linked to EDCs carries significant social and economic costs. This review evaluates regulatory frameworks, highlights methodological challenges in risk assessment, and synthesizes mechanistic and clinical evidence. Particular attention is given to unresolved issues such as non-monotonic dose responses, mixture effects, low-dose exposures, and transgenerational impacts. Future priorities include refining biomonitoring, addressing mixture risks, and strengthening international regulation. By integrating mechanistic, clinical, and policy insights, this review underscores the urgent need for strategies to mitigate EDC-related threats to male reproductive health.


  • Open Access

    Conservative Surgical Management of Adenomyosis: Implications for Infertility and Pregnancy Outcomes—A Perspective Review

    by Alexandra Ioannidou, Konstantinos Louis, Dimos Sioutis, Periklis Panagopoulos, Charalampos Theofanakis, Nikolaos Machairiotis

    Background/Objectives: Adenomyosis is increasingly being identified in women of childbearing age as a cause of infertility and adverse pregnancy outcomes. As hysterectomies are not suitable for fertile women, conservative surgical management has become a promising solution. We aimed to synthesize current evidence on conservative uterus-sparing surgical techniques for adenomyosis, focusing on implications for infertility treatment and pregnancy outcomes. Methods: A search of PubMed, Google Scholar, and Europe PMC from 2022 to July 2025 was conducted using combinations of the words “adenomyosis,” “fertility,” “infertility,” “pregnancy outcomes,” “adenomyomectomy,” and “uterine-sparing surgery.” Sixteen high-relevance studies were chosen that included reproductive-aged women who had conservative surgery for adenomyosis. Results: Excisional techniques such as adenomyomectomy yield pregnancy rates of >50% and live birth rates of up to 70% in focal disease, with less success in diffuse disease. Non-excisional approaches—high-intensity focused ultrasound (HIFU), radiofrequency ablation (RFA), and uterine artery embolization (UAE)—yield equivalent pregnancy (40–53%) and live birth (35–74%) rates in selected patients, with fewer surgical complications. Adjunctive hormonal therapy, particularly GnRH agonists, appears to improve outcomes. Risks include placenta accreta spectrum disorders and uterine rupture (≤6%), especially in diffuse adenomyosis. The type of lesion, location, and junctional zone thickness are strong predictors of fertility outcomes. Conclusions: Conservative surgery can augment fertility in appropriately chosen women with adenomyosis, with removal being the preferred treatment for focal disease and non-removal techniques offering encouraging alternatives in mild or intracorporeal disease. The addition of adjunct hormonal therapy and standardized patient selection criteria will optimize results. The lack of European professional society guidelines underscores the need for harmonized protocols in order to standardize the diagnosis, surgery, and reporting of results.


  • Open Access

    After the Shock: Impact of Ectopic Pregnancy on Subsequent Fertility and Parenthood

    by Efthalia Moustakli, Ekaterini Domali, Anastasios Potiris, Angeliki Gerede, Ismini Anagnostaki, Athanasios Zikopoulos, Charalampos Theofanakis, Nikolaos Kathopoulis, Konstantinos Louis, Peter Drakakis, et al.

    The potentially fatal condition known as ectopic pregnancy (EP) occurs when an embryo implants outside of the uterus, usually in the fallopian tube. It accounts for approximately 1–2% of all pregnancies and remains a leading cause of maternal morbidity in the first trimester. EP is an important area of focus in reproductive health that extends beyond its immediate clinical care. The purpose of this study is to investigate the effects of EP on the physical, reproductive, and psychological aspects of eventual fertility and parental outcomes. The findings from qualitative interviews, case–control studies, and cohort studies that have been published in peer-reviewed journals over the past 20 years were compiled into a narrative literature review. Included were studies looking at patient experiences after EP, psychosocial impacts, and reproductive results. According to research, women who have had EP in the past may have a slightly lower chance of becoming pregnant in the future, particularly following a salpingectomy. Assisted reproductive technology may potentially mitigate some of these risks. The parenting journey is often complicated by psychological consequences. Access to fertility services and counseling was found to have a significant impact on post-EP reproductive outcomes. The need for thorough follow-up care that addresses both physical and mental wellness is highlighted by the fact that EP can have long-lasting impacts on fertility and the parenting path. To optimize patient well-being and reproductive results, post-EP treatment must include early fertility counseling and psychological support.